Skip to main content

Table 3 Standard medication to reduce cardiovascular risk in MASTERPLAN

From: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]

Medication

Recommended dose

Point of impact

HMG-CoA Reductase Inhibitor (statin)

e.g. atorvastatin 10 mg daily (or comparable dose of other statin)

Lipid-metabolism

Acetylsalicylic acid

80 mg daily

Thrombocyte aggregation

Folic Acid

5 mg daily

Homocysteine metabolism

ACE inhibitor or Angiotensin Receptor Blocker (ARB)

e.g. enalapril 5 mg twice daily (or comparable dose of other ACE inhibitor) or irbesartan 75–150 mg (or comparable dose of other ARB) daily

Blood pressure, renal function and cardiac pre- and afterload

  1. a In case of proteinuria > 1 g/day: 125/75 mm Hg b NFN: Nederlandse Federatie voor Nefrologie (Dutch Federation for Nephrology) c KDOQI: Kidney Disease Outcomes Quality Initiative d NHG: Nederlands huisartsen genootschap (Dutch College of General Practitioners) e smaller than three times the upper limit of the normal range f GR: Gezondheidsraad (Health Council of the Netherlands) g NNGB: Nederlandse Norm voor Gezond Bewegen (Dutch Standard of Healthful Physical Activity)
Back to article page

Trials

ISSN: 1745-6215